These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 25664254

  • 21. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC, Wu YT, Yang WC, Tsai MJ, Liu JS, Yang CY, Li SY, Ou SM, Tarng DC, Hsu CC.
    PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
    [Abstract] [Full Text] [Related]

  • 22. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies.
    Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G.
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1511-25. PubMed ID: 18550651
    [Abstract] [Full Text] [Related]

  • 23. Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction.
    Loutradis C, Price A, Ferro CJ, Sarafidis P.
    J Hum Hypertens; 2021 Jun; 35(6):499-509. PubMed ID: 33654237
    [Abstract] [Full Text] [Related]

  • 24. Prevention of hypertension and its complications: theoretical basis and guidelines for treatment.
    Flack JM, Peters R, Shafi T, Alrefai H, Nasser SA, Crook E.
    J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S92-8. PubMed ID: 12819310
    [Abstract] [Full Text] [Related]

  • 25. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK.
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
    [Abstract] [Full Text] [Related]

  • 26. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S, López-Mesa M, Gómez-Fernández P.
    Nefrologia (Engl Ed); 2021 Sep; 41(3):258-275. PubMed ID: 36166243
    [Abstract] [Full Text] [Related]

  • 27. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A, Salazar J.
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [Abstract] [Full Text] [Related]

  • 28. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
    Luno J, Praga M, de Vinuesa SG.
    Curr Pharm Des; 2005 Sep; 11(10):1291-300. PubMed ID: 15853685
    [Abstract] [Full Text] [Related]

  • 29. Inhibition of the renin-angiotensin system in chronic kidney disease: a critical look to single and dual blockade.
    Locatelli F, Del Vecchio L, Cavalli A.
    Nephron Clin Pract; 2009 Sep; 113(4):c286-93. PubMed ID: 19729963
    [Abstract] [Full Text] [Related]

  • 30. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, Wright JM.
    Cochrane Database Syst Rev; 2015 Jan 11; 1():CD008170. PubMed ID: 25577154
    [Abstract] [Full Text] [Related]

  • 31. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
    Majewski C, Bakris GL.
    Curr Diab Rep; 2016 Apr 11; 16(4):24. PubMed ID: 26879307
    [Abstract] [Full Text] [Related]

  • 32. [Cardiovascular protection of diabetic patient with chronic renal disease and particular case of end-stage renal disease in elderly patients].
    Zaoui P, Hannedouche T, Combe C.
    Nephrol Ther; 2017 Jun 11; 13(6S):6S16-6S24. PubMed ID: 29463395
    [Abstract] [Full Text] [Related]

  • 33. Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists.
    Hsueh WA.
    Curr Opin Pharmacol; 2002 Apr 11; 2(2):182-8. PubMed ID: 11950631
    [Abstract] [Full Text] [Related]

  • 34. Dual renin-angiotensin system blockade for nephroprotection.
    Ruggenenti P.
    Nephrol Ther; 2017 Apr 11; 13 Suppl 1():S43-S45. PubMed ID: 28577742
    [Abstract] [Full Text] [Related]

  • 35. Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria.
    Coleman CI, Weeda ER, Kharat A, Bookhart B, Baker WL.
    Diabet Med; 2020 Jan 11; 37(1):44-52. PubMed ID: 31407377
    [Abstract] [Full Text] [Related]

  • 36. The Remission Clinic approach to halt the progression of kidney disease.
    Remission Clinic Task Force, Clinical Research Center "Aldo e Cele Daccò".
    J Nephrol; 2011 Jan 11; 24(3):274-81. PubMed ID: 21534237
    [Abstract] [Full Text] [Related]

  • 37. Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.
    Vasavada N, Agarwal R.
    F1000 Med Rep; 2009 Jun 09; 1():. PubMed ID: 20948734
    [Abstract] [Full Text] [Related]

  • 38. Renin-angiotensin system blockade in older adults with chronic kidney disease: a review of the literature.
    Weiss JW, Thorp ML, O'Hare AM.
    Curr Opin Nephrol Hypertens; 2010 Sep 09; 19(5):413-9. PubMed ID: 20539228
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of the renin-angiotensin system and chronic kidney disease.
    Siamopoulos KC, Kalaitzidis RG.
    Int Urol Nephrol; 2008 Sep 09; 40(4):1015-25. PubMed ID: 18704745
    [Abstract] [Full Text] [Related]

  • 40. Stimulation of Angiotensin Converting Enzyme 2: A Novel Treatment Strategy for Diabetic Nephropathy.
    Nomura H, Kuruppu S, Rajapakse NW.
    Front Physiol; 2021 Sep 09; 12():813012. PubMed ID: 35087423
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.